Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in Georgia
30 open options
- TRIALNARECRUITING
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
5 Sessions of Split-belt Treadmill-based Locomotor Adaptation — 1 site
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 212 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 145 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE3RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Donanemab · Placebo — 59 sites
- TRIALNARECRUITING
Inspiring Seniors Towards Exercise Promotion to Protect Cognition
Beat-accentuated, personalized music stimulation (BMS) · Strength Training (ST) · Aerobic exercise (AE) — 2 sites
- TRIALPHASE1RECRUITING
A Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers.
Intermittent deep brain stimulation of the nucleus basalis of Meynert — 1 site
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
KarXT · Placebo — 154 sites
- TRIALPHASE2RECRUITING
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
LHP588 · LHP588 · Placebo Drug — 40 sites
- TRIALPHASE2RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
BMS-986368 · Placebo — 75 sites
- TRIALNARECRUITING
GAMES Intervention in MCI (Mild Cognitive Impairment)
Online Gameplay Intervention · Waitlist control — 1 site
- TRIALNARECRUITING
Moving Yourself in Space and Time: MYSTIC
Complex Rhythmic Movement Sequences (CRMS) Sessions — 1 site
- TRIALPHASE1RECRUITING
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
AV-1980R 20 µg · AV-1980R 60 µg · AV-1980R 180 µg — 6 sites
- TRIALNAENROLLING_BY_INVITATION
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
MemorEM — 1 site
- TRIALPHASE1RECRUITING
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
LY3954068 · Placebo · Flortaucipir F18 — 10 sites
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALNAENROLLING_BY_INVITATION
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
Sensory Stimulation System (GS120) - Active — 53 sites
- TRIALNARECRUITING
Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)
Perturbation training — 1 site
- TRIALNAENROLLING_BY_INVITATION
DECIDE: Dyads and Families
Prototype Intervention — 4 sites
- TRIALNARECRUITING
Voice Technology-Based Self-Management Intervention
Voice-activated smart speakers — 1 site
- TRIALPHASE2RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
MK-2214 · Placebo — 80 sites
- TRIALPHASE3RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 143 sites
- TRIALNANOT_YET_RECRUITING
Assessing Treatment With High-phenolic EVOO Supplements for Neurovascular Activity
EVOO-phenolics dietary supplement · Placebo — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
KarXT · Placebo — 292 sites
- TRIALPHASE3RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
KarXT — 429 sites
- TRIALPHASE3RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 150 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
KarXT · KarX-EC · Placebo — 119 sites
- TRIALPHASE1RECRUITING
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
LY4006895 · Placebo — 13 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
KarXT · KarX-EC — 256 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.